The partnership with Charité is directly related to Evotec's core business of drug discovery and development, which is likely to be viewed positively by investors. The expansion of the molecular patient database could potentially lead to advancements in treatment for autoimmune diseases, signaling future growth opportunities for Evotec. This news is expected to have a positive short-term impact on Evotec's stock price, as it reflects the company's commitment to innovation and strategic growth within the healthcare sector.